The objective. Assessment of the effectiveness and safety of interferon-free therapy of chronic hepatitis C in ten liver recipients aged 46.9 ± 8.9 years, infected with hepatitis C virus genotype 1. Patients and methods. Fibrosis F0–F1 was found in eight patients. Five patients had an experience of treatment with pegilated interferons and ribavirin. Therapy consisted of includes ombitasvir + ritonavirin-boosted paritaprevir + dasabuvir plus ribavirin for 12 weeks; immunosuppressive therapy: tacrolimus or cyclosporin. Monitoring of clinico-laboratory parameters was performed every two weeks during treatment and six and twelve weeks after end of treatment. Results. After two weeks of treatment, viral load decreased to 8.4 × 10² IU/ml (р = 0.012). After four weeks of treatment viral load reached undetectable levels in three patients. On end of treatment and during follow-up period viral load remained at undetectable levels in all patients. After four weeks of treatment, cytolytic activity normalized. By EOT, thrombocyte levels increased to (156.4 ± 46.4) × 10⁹/l (р = 0.008). Adverse events – were presented by transitory increase of bilirubin levels in three patients, decrease of hemoglobin levels to 116.7 ± 19.8 g/l by the eighth week of therapy. Conclusion. Modern interferon-free regimens of antiviral therapy permit to obtain a stable virological response in liver recipients at maximally early and short terms.